You are here

Article Text

Article menu
Download PDFPDF
Treatment
Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder

https://doi.org/10.1136/ebn.8.2.45

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    March J, Silva S, Petrycki S, et al; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807–20.OpenUrlCrossRefPubMedWeb of Science

    Q In adolescents with major depressive disorder (MDD), how do fluoxetine, cognitive behavioural therapy (CBT), and their combination compare for effectiveness?

    METHODS

    Embedded ImageDesign:

    randomised controlled trial (RCT).

    Embedded ImageAllocation:

    {concealed}.*

    Embedded ImageBlinding:

    blinded (patients and healthcare providers [fluoxetine v placebo comparison], and outcome assessors).

    Embedded ImageFollow up period:

    12 weeks.

    Embedded ImageSetting:

    outpatient clinic in the US.

    Embedded ImagePatients:

    439 adolescents (mean age 15 y, 54% girls) who had a DSM-IV diagnosis of MDD, could attend an outpatient clinic, scored ⩾45 on the Children’s Depression Rating Scale–Revised (CDRS–R), had a full scale IQ ⩾80, and were not taking antidepressants. Exclusion criteria included bipolar disorder, severe conduct disorder, substance abuse/dependence, 2 failed selective serotonin reuptake inhibitor (SSRI) trials, and poor response …

    View Full Text

    Footnotes

    • ↵* Information provided by author.

    • ↵* Calculated from data in article.

    • For correspondence: Dr J S March, Department of Psychiatry, Duke University Medical Center, Durham, NC, USA. jsmarchacpub.duke.edu

    • Sources of funding: National Institute of Mental Health; fluoxetine and placebo supplied by Lilly Inc.